Posted on 11/02/2010 in Pharmaceutical Company Product News Roche has announced the results of five phase III clinical trials into its type 2 diabetes treatment taspoglutide.
During the studies, taspoglutide met the primary endpoints of reduction in blood glucose (blood sugar), indicating that the first weekly human GLP-1 analogue may improve treatment options for patients with type 2 diabetes.
Furthermore, the drug was well-tolerated in all five trials, with the most common adverse events among patients being nausea and vomiting.
Hal Barron, global head of product development at Roche, commented: "These Phase III studies have shown that treatment with once weekly taspoglutide leads to significantly improved blood glucose control, consistent weight loss, a minimal risk of hypoglycaemia and manageable safety profile."
Earlier this month, Roche published its financial results for the whole of 2009, revealing record sales and double-digit growth in operating profit.
Group sales increased to 49.1 billion Swiss francs (29.16 billion pounds) - representing a rise of ten per cent.Other news stories from 11/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
